Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial by Siena, Salvatore, MD, Di Bartolomeo, Maria, MD, Raghav, Kanwal, MD, Masuishi, Toshiki, MD, Loupakis, Fotios, MD, Kawakami, Hisato, MD, Yamaguchi, Kensei, MD, Nishina, Tomohiro, MD, Fakih, Marwan, MD, Elez, Elena, MD, Rodriguez, Javier, MD, Ciardiello, Fortunato, MD, Komatsu, Yoshito, MD, Esaki, Taito, MD, Chung, Ki, MD, Wainberg, Zev, MD, Sartore-Bianchi, Andrea, MD, Saxena, Kapil, MD, Yamamoto, Eriko, BSPS, Bako, Emarjola, MD, Okuda, Yasuyuki, MPH, Shahidi, Javad, MD, Grothey, Axel, MD, Yoshino, Takayuki, MD

Get full text

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study by Tamura, Kenji, MD, Tsurutani, Junji, Prof, Takahashi, Shunji, MD, Iwata, Hiroji, MD, Krop, Ian E, MD, Redfern, Charles, MD, Sagara, Yasuaki, MD, Doi, Toshihiko, MD, Park, Haeseong, MD, Murthy, Rashmi K, MD, Redman, Rebecca A, MD, Jikoh, Takahiro, MS, Lee, Caleb, MD, Sugihara, Masahiro, PhD, Shahidi, Javad, MD, Yver, Antoine, MD, Modi, Shanu, MD

Get full text

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study by Shitara, Kohei, MD, Iwata, Hiroji, MD, Takahashi, Shunji, MD, Tamura, Kenji, MD, Park, Haeseong, MD, Modi, Shanu, MD, Tsurutani, Junji, Prof, Kadowaki, Shigenori, MD, Yamaguchi, Kensei, MD, Iwasa, Satoru, MD, Saito, Kaku, MS, Fujisaki, Yoshihiko, MS, Sugihara, Masahiro, PhD, Shahidi, Javad, MD, Doi, Toshihiko, MD

Get full text